跳到主要內容
Quest Diagnostics Home.

分子測試幫助診斷Covid-19(測試代碼39448)

At Quest, we’re committed to serving our communities and connecting our customers to answers quickly and reliably every day.

\r\n

We will continue to prioritize and expedite testing for priority patients (i.e., hospitalized patients, individuals in long-term care such as nursing homes, and presurgical patients) as we have done since the beginning of the pandemic. Please visit the CDC guidelines for the latest on who should get tested.
\r\n

\r\n

This website is kept up to date and represents current average turnaround times nationally.
\r\n

\r\n","@type":"corporate/components/text"}}" id="text-3175ebc3f7" class="cmp-text">

在任務中,我們致力於為我們的社區提供服務,並將客戶與每一天快速和可靠地答案。

我們將繼續優先考慮優先患者的優先考驗和加快檢測,因為自大流行開始以來,我們所做的那樣,我們的優先患者(即住院患者,養老院,養老院和前訓練患者)。請訪問CDC指南對於最新的誰應該得到測試。

本網站保持最新,並表示當前的平均周轉時間。

優先患者

At Quest, we continue to prioritize molecular testing and TAT for Priority patients. Priority testing parameters are defined as hospitalized, long-term care (LTC), and presurgical patients.

\r\n","@type":"corporate/components/text"}}" id="text-a74ba1a0a8" class="cmp-text">

在任務,我們繼續優先考慮分子測試和優先患者的TAT。優先測試參數被定義為住院,長期護理(LTC)和前牙科患者。

總人口

COVID-19 is unpredictable, and we will continue to monitor the situation closely should changing dynamics affecting demand, supplies, and other factors cause our expectations for turnaround time to slip. 

\r\n","@type":"corporate/components/text"}}" id="text-6e855cdcd0" class="cmp-text">

covid-19是不可預測的,而且我們將繼續密切監察這種情況應該改變影響需求,用品和其他因素的動態,導致我們對周轉時間滑動的預期。

Please contact your Quest representative to obtain the turnaround time at your specific laboratory location or for more information around COVID-19 testing.

\r\n","@type":"corporate/components/text"}}" id="text-e2019708d9" class="cmp-text">

請聯係您的Quest代表,以獲得特定實驗室位置的周轉時間,或有關Covid-19測試的更多信息。

Covid-19測試陳述

\r\n
  • The antibody tests and the molecular tests (together “All tests”) have not been FDA cleared or approved;
  • \r\n
  • All tests have been authorized by FDA under EUAs for use by authorized laboratories;
  • \r\n
  • The antibody tests have been authorized only for the detection of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens;
  • \r\n
  • The molecular tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses, pathogens; and,
  • \r\n
  • All tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
  • \r\n\r\n","@type":"corporate/components/text"}}" id="text-516f4a2d8e" class="cmp-text">
    • 抗體試驗和分子試驗(一起“所有測試”)尚未被FDA清除或批準;
    • 所有測試已由FDA授權歐盟以授權實驗室使用;
    • 抗體試驗僅授權用於檢測針對SARS-COV-2的IgG抗體,而不是任何其他病毒或病原體;
    • 分子試驗僅授權用於檢測來自SARS-COV-2的核酸,而不是任何其他病原體;和,
    • 所有測試僅授權宣布持續時間,情況存在證明在第564(b)(b)(1)條第564(b)(b)(1)條第564(b)(1)條第564(b)(1)條第564(b)(b)(b)(1)條第564(b)(b)(1)條規定的授權授權。§360bbb-3(b)(1),除非授權迅速終止或撤銷。

    在Covid-19健康危機期間,比以往任何時候都更快速行動和信任信息。

    找出正在發生的事情

    了解更多
    Baidu
    map